Sébastien PELTIER, CEO

Standing among the 100 personalities "beyond diabetes".

VALEDIA®

Confirms its potential to reduce the risk of type 2 diabetes.

Inauguration of VALBIOTIS’ R&D Center

The Discovery and Preclinical Research Platform at Riom: a state-of-the-art GLP-standard infrastructure.

S c r o l l

Products

.01

Pipeline

5 products in clinical development

Learn more

.02

VALEDIA®

Prediabetes
• Reduction of the risk of type 2 diabetes
• Phase IIa clinical study ongoing

Learn more

.03

LpD64

Overweight and /or obesity
• Modulation of intestinal microbiota
• Clinical Phase I/II positive

Learn more

.04

VAL-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

Learn more

.05

VAL-63-NAFLD

Non-alcoholic fatty liver (NAFL)
• Reduction of NAFL, risk factor for NASH
• Clinical Phase I/II positive

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

09.10.2018

European Large & Midcap Event 

En savoir plus
03.10.2018

European Association for the Study of Diabetes (EASD) Congress

En savoir plus
27.09.2018

100 portraits beyond diabetes

En savoir plus
05.09.2018

Biotech Santé Portzamparc Conference

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Follow us!

See more